Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

24. Januar 2017 13:03 ET | Quelle: VAYA Pharma Inc.

CORRECTING and REPLACING -- Improved Academic Performance and Medication Rebound in Patients with ADHD Following the Use of Vayarin®, a Multi-Year, Real-World Retrospective Study

BALTIMORE, Jan. 24, 2017 (GLOBE NEWSWIRE) -- In a release issued under the same headline January 10, 2017 by VAYA Pharma, please note that in the first paragraph under Results at a Glance, "38...
10. Januar 2017 11:33 ET | Quelle: VAYA Pharma Inc.

Improved Academic Performance and Medication Rebound in Patients with ADHD Following the Use of Vayarin®, a Multi-Year, Real-World Retrospective Study

BALTIMORE, Jan. 10, 2017 (GLOBE NEWSWIRE) -- Up to 75 percent of individuals with Attention Deficit Hyperactivity Disorder (ADHD) experience emotional dysregulation, according to Research in...
10. September 2014 20:36 ET | Quelle: Robbins LLP

Robbins Arroyo LLP: Enzymotec Ltd. (ENZY) Stock Falls Nearly 40% After Violations of Federal Law are Revealed, According to Class Action

SAN DIEGO and MIGDAL HAEMEK, Israel, Sept. 10, 2014 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Enzymotec Ltd. (Nasdaq:ENZY) has filed a federal...